- Home
- RIV vs OLMA Comparison
RIV vs OLMA Comparison
Compare RIV & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- OLMA
- Stock Information
- Founded
- RIV 2015
- OLMA 2006
- Country
- RIV United States
- OLMA United States
- Employees
- RIV N/A
- OLMA N/A
- Industry
- RIV Finance Companies
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- RIV Finance
- OLMA Health Care
- Exchange
- RIV Nasdaq
- OLMA Nasdaq
- Market Cap
- RIV 264.7M
- OLMA 289.0M
- IPO Year
- RIV N/A
- OLMA 2020
- Fundamental
- Price
- RIV $10.92
- OLMA $4.42
- Analyst Decision
- RIV
- OLMA Strong Buy
- Analyst Count
- RIV 0
- OLMA 3
- Target Price
- RIV N/A
- OLMA $27.67
- AVG Volume (30 Days)
- RIV 87.6K
- OLMA 1.2M
- Earning Date
- RIV 01-01-0001
- OLMA 05-07-2025
- Dividend Yield
- RIV 12.85%
- OLMA N/A
- EPS Growth
- RIV N/A
- OLMA N/A
- EPS
- RIV N/A
- OLMA N/A
- Revenue
- RIV N/A
- OLMA N/A
- Revenue This Year
- RIV N/A
- OLMA N/A
- Revenue Next Year
- RIV N/A
- OLMA N/A
- P/E Ratio
- RIV N/A
- OLMA N/A
- Revenue Growth
- RIV N/A
- OLMA N/A
- 52 Week Low
- RIV $9.63
- OLMA $2.86
- 52 Week High
- RIV $12.43
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- RIV 37.13
- OLMA 60.78
- Support Level
- RIV $10.79
- OLMA $2.96
- Resistance Level
- RIV $11.25
- OLMA $3.41
- Average True Range (ATR)
- RIV 0.42
- OLMA 0.35
- MACD
- RIV -0.02
- OLMA 0.16
- Stochastic Oscillator
- RIV 43.81
- OLMA 98.73
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.